Have a feature idea you'd love to see implemented?
Let us know!
SCYX Scynexis Inc
Price (delayed)
$1.19
Market cap
$45.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.76
Enterprise value
$31.78M
SCYNEXIS, Inc. is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Its lead candidate, ibrexafungerp (formerly
Highlights
Scynexis's gross margin has shrunk by 172% YoY and by 28% QoQ
The company's EPS has shrunk by 150% YoY and by 2.7% QoQ
Key stats
What are the main financial stats of SCYX
Market
Valuations
Earnings
Shares outstanding
37.95M
Market cap
$45.16M
Enterprise value
$31.78M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.77
Price to sales (P/S)
6.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.71
Revenue
$8.57M
EBIT
-$35.33M
EBITDA
-$35.2M
Free cash flow
-$21.84M
Per share
Balance sheet
Liquidity
EPS
-$0.76
Free cash flow per share
-$0.45
Book value per share
$1.55
Revenue per share
$0.18
TBVPS
$2.04
Total assets
$99.04M
Total liabilities
$40.51M
Debt
$15.9M
Equity
$58.53M
Working capital
$54.74M
Debt to equity
0.27
Current ratio
3.13
Quick ratio
3.07
Net debt/EBITDA
0.38
Margins
Efficiency
Dividend
EBITDA margin
-410.9%
Gross margin
-71.4%
Net margin
-425.4%
Operating margin
-608.6%
Return on assets
-32.1%
Return on equity
-54.8%
Return on invested capital
-48%
Return on capital employed
-48.2%
Return on sales
-412.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SCYX stock price
How has the Scynexis stock price performed over time
Intraday
0.85%
1 week
-5.56%
1 month
-21.71%
1 year
-27.88%
YTD
-46.64%
QTD
-20.13%
Financial performance
How have Scynexis's revenue and profit performed over time
Revenue
$8.57M
Gross profit
-$6.12M
Operating income
-$52.13M
Net income
-$36.44M
Gross margin
-71.4%
Net margin
-425.4%
Scynexis's gross margin has shrunk by 172% YoY and by 28% QoQ
SCYX's operating income has shrunk by 171% YoY
The company's net income has shrunk by 150% YoY and by 3% QoQ
The gross profit has shrunk by 105% YoY and by 13% QoQ
Growth
What is Scynexis's growth rate over time
Valuation
What is Scynexis stock price valuation
P/E
N/A
P/B
0.77
P/S
6.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.71
The company's EPS has shrunk by 150% YoY and by 2.7% QoQ
SCYX's price to book (P/B) is 83% lower than its 5-year quarterly average of 4.5 and 23% lower than its last 4 quarters average of 1.0
The equity has declined by 36% year-on-year and by 3.1% since the previous quarter
Scynexis's revenue has shrunk by 94% YoY and by 11% QoQ
The P/S is 94% lower than the 5-year quarterly average of 117.4 but 38% higher than the last 4 quarters average of 4.9
Efficiency
How efficient is Scynexis business performance
Scynexis's return on assets has shrunk by 151% YoY and by 14% QoQ
SCYX's return on invested capital has dropped by 149% year-on-year and by 19% since the previous quarter
The return on equity has dropped by 130% year-on-year and by 16% since the previous quarter
The company's return on sales fell by 18% QoQ
Dividends
What is SCYX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SCYX.
Financial health
How did Scynexis financials performed over time
The total assets is 144% more than the total liabilities
The current ratio has plunged by 59% YoY and by 17% from the previous quarter
Scynexis's quick ratio has shrunk by 54% YoY and by 17% QoQ
Scynexis's debt is 73% less than its equity
The company's debt to equity has surged by 69% YoY and by 3.8% QoQ
The equity has declined by 36% year-on-year and by 3.1% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.